Evonik EVK.DE
What does Evonik do?
Evonik is a German specialty chemicals group headquartered in Essen with a global presence. The company manufactures products that are used in other industries as intermediates or additives. These include silicas and silanes for tires and electronics, amino acids such as methionine and lysine for animal nutrition, hydrogen peroxide, and additives for coatings, adhesives and foams.
The business is divided into the segments Advanced Technologies, Custom Solutions and Infrastructure. Customers are mainly manufacturers in automotive, construction, consumer goods, pharmaceuticals, cosmetics and the animal feed industry. Competitively, Evonik positions itself through technological specialization, proximity to applications and leading market positions in niches. In standardized products such as feed amino acids, the company faces price competition from international providers, particularly from Asia. Competitors include large chemical groups such as BASF, Wacker, Dow and Arkema.
Score profile
Rank vs. Specialty Chemicals (43 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.
Metrics compared with the industry
On profitability and quality, Evonik ranks below average in the group Specialty Chemicals (2.4/10). On growth, the company ranks above average in the group Specialty Chemicals (6.2/10). On valuation (higher = cheaper), the stock ranks in the middle in the group Specialty Chemicals (5.8/10). On financial strength, Evonik ranks in the middle in the group Specialty Chemicals (5.7/10).
| Metric | Stock | Group median | Ranking |
|---|---|---|---|
| Forward P/E | 13.9x | 15.7x | better than 66 % |
| Trailing P/E | 57.6x | 29.6x | better than 15 % |
| PEG ratio | 6.2x | 2.0x | better than 4 % |
| EV/EBITDA | 8.6x | 11.9x | better than 78 % |
| Price/sales | 0.7x | 1.6x | better than 83 % |
| Price/book | 1.3x | 2.3x | better than 80 % |
| Revenue growth | 12.8% | 7.9% | better than 85 % |
| Earnings growth | 0.0% | 0.0% | better than 39 % |
| Gross margin | 24.7% | 31.7% | better than 31 % |
| Operating margin | 5.4% | 12.2% | better than 17 % |
| Net margin | 1.2% | 5.3% | better than 20 % |
| Return on equity | 2.2% | 8.7% | better than 27 % |
| Debt/equity | 48.9% | 68.5% | better than 77 % |
| Current ratio | 1.3x | 1.8x | better than 13 % |
| Free cash flow yield | 8.4% | 3.5% | better than 80 % |
| Dividend yield | 4.7% | 1.8% | – |
| Payout ratio | 270.3% | 48.8% | – |
| Beta | 0.50 | 0.86 | – |
Valuation: what is Evonik worth?
Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Evonik a model range of 24.07 EUR to 50.00 EUR per share.
11 analysts, average rating “Hold”, average price target 19.55 EUR (−8.3%).
The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.
What the business depends on
- Demand from customer industries such as automotive, construction, animal nutrition and electronics largely determines sales volumes.
- Technologically differentiated specialty products enable better prices and margins than pure commodity chemicals.
- Cost efficiency, plant utilization, and raw material and energy prices significantly affect profitability.
Risks
- High energy and raw material costs at the German location can weigh on competitiveness against international providers.
- Economic fluctuations in cyclical customer industries lead to volatile demand and price pressure.
- Price competition in standardized products, as well as regulatory requirements and restructuring costs, can weigh on results.
What to look for with Evonik
The adjusted EBITDA margin is particularly informative, as it shows how well specialization and cost control convert prices into earnings in a cyclical, capital-intensive business.